Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

MISSISSAUGA, ON, April 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today reported the results of operations for the three months ended February 29, 2008. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At February 29, 2008, our cash and cash equivalents totaled $19.9 million, compared with $23.5 million at November 30, 2007.

We incurred a net loss for the three months ended February 29, 2008, of $5.3 million, or $0.24 per common share, compared with a net loss of $7.7 million, or $0.47 per common share for the same period in 2007. A key driver of this decrease was a $1.6 million reduction in expenses resulting from the repayment of the senior convertible notes in April 2007, and lower infrastructure and other support costs driven by lower employee numbers in 2008.

For the three months ended February 29, 2008, research and development expenses decreased to $2.8 million from $3.0 million for the comparable period in 2007. During the first quarter of 2008, these costs were incurred for the initial commercialization of Celacade in Europe and for preparations for ACCLAIM II, a study designed to evaluate the Celacade technology for the treatment of patients with NYHA Class II heart failure.

General and administration expenses were $2.7 million for the three months ended February 29, 2008, compared to $3.6 million for the same period in 2007 as a result of lower employee numbers.

Highlights

- In January, preclinical findings demonstrating that VP025, the lead

candidate from our VP series of drugs, provides a significant

neuroprotective effect in a model of Parkinson's disease were

published in the European Jou
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Fresne, President and CEO of Egenix, Inc. is pleased to ... its Scientific Advisory Committee. Dr. Vagner, a graduate ... performed research at Embl (European Molecular Biology Laboratory) Heidelberg, ... of health and medical research. He is a Research Director ... France , and at the Gustave Roussy ...
(Date:9/16/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... the Company,s Investor Day in New ... syndrome (IBS) program, including its novel, oral product ... the keynote presentation, Mark Pimentel , MD, ...
(Date:9/16/2014)... LOUISVILLE, Ky. , Sept. 16, 2014 /PRNewswire/ ... laboratory technologies and products to hospitals, physician office ... announce that, effective October 1, 2014, it will ... in specified hospital market segments and as a ... in the 48 contiguous United States ...
(Date:9/16/2014)... Sept. 16, 2014 In preparation for VARTECH ... -based cybersecurity company focused on authentication and SSO announced ... the ability to generate a OTP through the presentation ... pioneer of user-based RFID authentication, 2FA,s solutions have leveraged ... for many years. RFID authentication is broadly deployed in ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 32FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2
... HILL, N.C., June 10 Pharmaceutical companies can,literally ... in the lifetime cash,flows of potential mega-brands. Research ... of a new product. Sales and Marketing teams ... table at which market success is,determined., Best ...
... provide resources to advance Merrimack,s robust pipeline of biologics ... targeting autoimmune disease and cancer, ... focused on the discovery and development of,novel treatments for autoimmune ... in a Series F private equity financing., Existing and ...
... Pharmaceuticals,Inc. and The Leukemia & Lymphoma Society (LLS) ... to advance the development of a treatment,for acute ... contracted with Provid to supply expert,medicinal chemistry services ... (SCOR) grant at the University of Virginia under ...
Cached Biology Technology:Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia 2The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia 3
(Date:9/16/2014)... chunk of rock hit the Yukatan peninsula near the site ... 100 teratons of TNT. It left a crater more than ... and volcanism are widely accepted to have wiped out the ... But what happened to the plants on which the dinosaurs ... University of Arizona reveals that the meteorite impact that spelled ...
(Date:9/16/2014)... returned to Spain culminating the around the world of ... of how the global ocean works and what is ... the atmosphere is not limited to coastal areas, but ... planet, and it is already affecting the ocean ecosystem. ... CSIC Residence for Researchers in Barcelona, in a congress ...
(Date:9/16/2014)... the salmon-rich waters of Southeast Alaska to the white ... lobster, lumber and tourist towns, coastal residents around the ... environments divide along political lines. That,s a primary finding ... sociologists published this month in the journal Society ... of environment-related differences from place to place to place. ...
Breaking Biology News(10 mins):Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3
... Ohio -- Engineers at Ohio State University have found ... alternative energy resource. The patented process uses eggshells ... produces hydrogen fuel. It also includes a unique method ... the shells, so that the collagen can be used ...
... 2007Analyses conducted by researchers from Universit Lavals Center for ... affected by climate change. In an article to be ... Letters, the international research team led by Universit Laval ... life in Ward Hunt Lake, a body of water ...
... months last spring, the Vanderbilt greenhouse held more members ... known to exist in the wild., This unusual bounty ... Ellis, a doctoral student in the biological sciences department, ... The species is called the giant whorled sunflower, Helianthus ...
Cached Biology News:Engineered eggshells to help make hydrogen fuel 2Engineered eggshells to help make hydrogen fuel 3North America's northernmost lake affected by global warming 2Student study bolsters case for adding a rare sunflower to the endangered species list 2
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... VersaDoc MP 4000 System is a ... system capable of supporting a wide ... chemiluminescence, densitometry, and chemiflourescence. Red, ... imaging of multiplexed fluorescent samples, reducing ...
... hydrophobic barrier pen for immunohistochemistry and in ... frozen or paraffin-embedded tissue sections mounted on ... heat-stable, water-repellent barrier that keeps staining reagents ... of reagents when differentially staining two sections ...
Biology Products: